<DOC>
	<DOCNO>NCT00097825</DOCNO>
	<brief_summary>The goal study determine effectiveness safety annual intravenous treatment zoledronic acid treatment osteoporosis men . All patient receive calcium vitamin D supplement .</brief_summary>
	<brief_title>Efficacy Safety Zoledronic Acid Treatment Osteoporosis Men</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Male , 2585 year old Current user bisphosphonates Aredia® ( pamidronate ) , Didronel® ( etidronate ) , Fosamax® ( alendronate ) , Actonel ® ( residronate ) , Skelid® ( tiludronate ) History severe liver , kidney eye disease Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Male Osteoporosis</keyword>
</DOC>